Akari Therapeutics Plc (AKTX) stock: price, suppliers, customers and institutional ownership
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Akari Therapeutics Plc
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
Nasdaq · Manufacturing
Prev close 10.52 · gapped below the open, then crossed back over prior close. High/low 10.93 at 9:45 am ET, 10.07 at 4:00 am ET.
Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid. Akari Therapeutics, Plc is based in London, the United Kingdom.
No case yet. It builds on the next filing, report or 13F period.
No peer readings for Akari Therapeutics Plc yet.
3 managers report a position worth $2,079 between them, and 1 of them hold 80% of it.
tall tick = annual report · 1 on record
AKTX (Akari Therapeutics Plc) has 0 disclosed suppliers and 0 disclosed customers, strongest disclosure first.
Select a tie for the filing sentence that discloses it; select again to open the company. Lines are disclosed suppliers and customers, coloured by industry; the closer to the centre, the more the filings disclose. A dot is green or red by today’s move. Extended: satellites hang off single companies, not bundled sectors.